Overview

A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Astellas Pharma US, Inc.